pubmed-article:6588929 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:6588929 | lifeskim:mentions | umls-concept:C0040517 | lld:lifeskim |
pubmed-article:6588929 | lifeskim:mentions | umls-concept:C0007806 | lld:lifeskim |
pubmed-article:6588929 | lifeskim:mentions | umls-concept:C1149831 | lld:lifeskim |
pubmed-article:6588929 | pubmed:issue | 7 | lld:pubmed |
pubmed-article:6588929 | pubmed:dateCreated | 1984-7-31 | lld:pubmed |
pubmed-article:6588929 | pubmed:abstractText | Cerebrospinal fluid acetylcholinesterase (AChE) activity was studied as a possible marker for central cholinergic neuronal function in seven patients with Gilles de la Tourette's syndrome. No significant differences were found between CSF AChE activity in untreated or haloperidol-treated patients and control populations. These data do not appear to support a pathophysiologic association between the cholinergic system and Gilles de la Tourette's syndrome. | lld:pubmed |
pubmed-article:6588929 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6588929 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6588929 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6588929 | pubmed:language | eng | lld:pubmed |
pubmed-article:6588929 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6588929 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:6588929 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6588929 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:6588929 | pubmed:month | Jul | lld:pubmed |
pubmed-article:6588929 | pubmed:issn | 0003-9942 | lld:pubmed |
pubmed-article:6588929 | pubmed:author | pubmed-author:CoyleJ TJT | lld:pubmed |
pubmed-article:6588929 | pubmed:author | pubmed-author:SingerH SHS | lld:pubmed |
pubmed-article:6588929 | pubmed:author | pubmed-author:OshidaLL | lld:pubmed |
pubmed-article:6588929 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:6588929 | pubmed:volume | 41 | lld:pubmed |
pubmed-article:6588929 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:6588929 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:6588929 | pubmed:pagination | 756-7 | lld:pubmed |
pubmed-article:6588929 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
pubmed-article:6588929 | pubmed:meshHeading | pubmed-meshheading:6588929-... | lld:pubmed |
pubmed-article:6588929 | pubmed:meshHeading | pubmed-meshheading:6588929-... | lld:pubmed |
pubmed-article:6588929 | pubmed:meshHeading | pubmed-meshheading:6588929-... | lld:pubmed |
pubmed-article:6588929 | pubmed:meshHeading | pubmed-meshheading:6588929-... | lld:pubmed |
pubmed-article:6588929 | pubmed:meshHeading | pubmed-meshheading:6588929-... | lld:pubmed |
pubmed-article:6588929 | pubmed:meshHeading | pubmed-meshheading:6588929-... | lld:pubmed |
pubmed-article:6588929 | pubmed:meshHeading | pubmed-meshheading:6588929-... | lld:pubmed |
pubmed-article:6588929 | pubmed:meshHeading | pubmed-meshheading:6588929-... | lld:pubmed |
pubmed-article:6588929 | pubmed:year | 1984 | lld:pubmed |
pubmed-article:6588929 | pubmed:articleTitle | CSF cholinesterase activity in Gilles de la Tourette's syndrome. | lld:pubmed |
pubmed-article:6588929 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:6588929 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:6588929 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |